Lineage Cell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of up to a $66 Million Registered Direct Offering. Also, D Boral Capital Maintained a Buy Rating on the Stock and Lowered Its Price Target From $3 to $2.
Lineage Cell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of up to a $66 Million Registered Direct Offering. Also, D Boral Capital Maintained a Buy Rating on the Stock and Lowered Its Price Target From $3 to $2.
Lineage cell therapeutics的股票在公司宣佈高達6600萬註冊直接發行的定價後交易下跌。此外，D Boral Capital維持對該股票的買入評級，並將其目標價從3美元下調至2美元。
Lineage Cell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of up to a $66 Million Registered Direct Offering. Also, D Boral Capital Maintained a Buy Rating on the Stock and Lowered Its Price Target From $3 to $2.
Lineage Cell Therapeutics宣佈了高達6600萬美元的註冊直接發行的定價後，該公司股價走低。此外，D Boral Capital維持該股的買入評級，並將其目標股價從3美元下調至2美元。
資訊熱榜
更新時間